ANI Pharmaceuticals Inc (ANIP)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-18,522	-7,091	27,015	35,547	18,779	13,381	-5,159	-26,327	-47,896	-67,789	-63,636	-62,819	-42,608	-22,107	-17,238	-15,468	-22,560	-23,760	-20,350	-1,536
Total stockholders’ equity	US$ in thousands	428,530	430,798	455,760	451,963	432,749	454,711	434,472	339,482	338,540	336,675	336,958	346,094	358,740	191,403	191,917	203,712	195,700	195,100	191,344	201,171
ROE		-4.32%	-1.65%	5.93%	7.87%	4.34%	2.94%	-1.19%	-7.76%	-14.15%	-20.13%	-18.89%	-18.15%	-11.88%	-11.55%	-8.98%	-7.59%	-11.53%	-12.18%	-10.64%	-0.76%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-18,522K ÷ $428,530K
= -4.32%

ANI Pharmaceuticals Inc's return on equity (ROE) has shown a declining trend over the past few years, starting in negative territory and gradually improving from March 31, 2023, onwards. The negative ROE figures indicate that the company's net income was insufficient to generate a positive return for shareholders based on the equity invested.

The improvement in ROE from March 31, 2023, to December 31, 2024, suggests that ANI Pharmaceuticals Inc has been able to enhance its profitability and efficiency in utilizing shareholders' equity to generate earnings. The positive ROE figures seen in the last few quarters indicate that the company has started generating a reasonable return on the equity capital provided by its shareholders.

Overall, while the recent positive ROE figures are a positive sign, ANI Pharmaceuticals Inc should continue to focus on sustaining and improving its profitability to ensure long-term shareholder value creation.